Fieldex Exploration Announces Termination of Proposed Reverse Take-over with Copeland Biosciences Corp.
As a result of the termination of the two agreements, Fieldex will not proceed with the Reverse Take-over. Fieldex will focus on finding other opportunities to increase shareholder value. In addition, none of the resolutions relating to the Reverse Take-over approved by Fieldex shareholders at the annual and special meeting held on August 5, 2019 will be carried out, including the change of Fieldex's corporate name to "Copeland Biosciences Corp", the change of the province in Canada where the registered office of Fieldex is located from Québec to Ontario, the voluntary delisting of the common shares of Fieldex from the TSX Venture Exchange ("TSXV") and the listing of the common shares of Fieldex on the Canadian Securities Exchange. There is no penalty receivable or payable by Fieldex in connection with the termination of the Reverse Take-over.
Trading in Fieldex's shares was halted on June 6, 2017 in accordance with the policies of TSXV. Given the termination of the Business Combination Agreement and Amalgamation Agreement, Fieldex will file an application with the TSXV to request that trading of its common shares resume. Fieldex will confirm in press release the date, if any, on which trading in its common shares will resume on the TSXV.
About Fieldex
Fieldex is a mineral resource company based in Québec. As of the date hereof, Fieldex has 15,668,023 common shares issued and outstanding.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact
Fieldex Exploration Inc.
Martin Dallaire, eng, President & Chief Executive Officer
Tel.: (819) 762-0609, Fax: (819) 762-0097
mdallaire@fieldexexploration.com
www.fieldexexploration.com